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Erika Melman, MSN-RN    
DePaul University, NSG598: Graduate Research Synthesis  
To date, tissue plasminogen activator (tPA) 
is one of the only FDA approved treatments 
for patients presenting with symptomatic 
ischemic stroke. The narrow therapeutic 
window range of 3 – 4.5 hours poses a 
serious set-back in recovery and neurological 
remediation rates. Furthermore, the vast 
majority of stroke patients cannot get access 
to treatment within the narrowly defined 
time limits. Beyond the acute time period, 
there is evidence that physical rehabilitation 
focused on the injured area is effective. 
However, neurological recovery with physical 
rehabilitation is rarely complete.  
tPA is an inadequate treatment for 
stroke. The narrow therapeutic window 
of tPA does not allow for timely 
reperfusion in turn hindering the 
possibility of neurologic remediation. 
While there are other treatment 
modalities available for use today, they 
are under-utilized in the hospital 
setting to date. There are multiple 
suggested treatment modalities, 
both pharmacologic and non-
pharmacologic that have shown 
promise in areas such as physically 
treating the occlusion and increasing 
neurologic function post stroke. 
These treatment modalities need to be 
researched more in depth. Current 
clinical trials being run on alternative 
therapies such as stem cells and new 
pharmacological interventions that 
seem to show promise in increasing 
neurologic functions post-ischemic 
stroke. Hopefully, through research, 
clinical trails and new medical 
advances, new treatment modalities 
that will increase the rate of recovery 
post-stroke and decrease the damage 
done to brain tissue is in our near 
future. 
 
Suggested Therapies 
Current Therapies 
Conceptual Framework Conclusions and 
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Gadhia, J., Starkman, S., Ovbiagele, B., Ali, L., Liebeskind, D., & Saver, J. (2010). Assessment and Improvement of Figures to 
Visually Convey Benefit and Risk of Stroke Thrombolysis. American Heart Association . doi:10.7554/elife.27518.007 
In this review, the four constructs of the 
Health Belief Model - initial threat to health, 
cue to action, perceived benefits outweighing 
barriers/risks and undertaking of 
preventative action have guided the entirety 
of this project in design, reporting and 
evaluation of the current standards, 
knowledge and treatments ischemic stroke 
(see below) 
²  tPa 
²  Despite high morbidity, mortality and cost, 
only treatment with clinical efficacy 
²  Intracranial thrombolysis 
²  Localized tPA in area of occlusion 
²  Mechanical 
²  Guided catheter to clear and aspirate 
occlusion 
²  Stem Cells 
²  Suggested in the use of neuroregeneration 
post stroke by replacing the cells that have 
died with stem cells to replicate and function 
as human cells  
²  G-CSF 
²  Endogenous stem cells - studies suggest 
improved neurological remediation and 
reduced damage to brain tissue  
²  Citicoline 
²  Endogenous stem cells – may inhibit ischemic 
cascade and increase neuroplasticity 
²  Mild Hypothermia 
²  Salvage or post-pone damage to 
compromised brain tissue 
²  tenecteplase 
²  Genetically mutated form of tPA – longer half-
life with more fibrin specificity = faster clot 
lysis with less bleeding 
Methods 
Research Questions 
1.  What current therapies are clinically 
proven most effective and used most 
commonly in increasing neurologic 
function post ischemic stroke? 
 
2.  What is the safest and most effective 
treatment to date for an ischemic stroke 
to reduce permanent neurological 
dysfunction? 
An integrative literature review was used to 
assess and report on current stroke therapy 
effectiveness and possible reported 
alternative therapies for the purpose of 
decreasing the degree of irreversible 
neurological damage sustained from tissue 
ischemia during an ischemic stroke. After 
research articles were compiled and 
inclusion/exclusion criteria was applied, five 
articles were deemed to have sufficient 
evidence to be included in this literature 
review. 
 
